Full-Time

Director/VP of Strategy & Operations

Roivant Sciences

Roivant Sciences

201-500 employees

Biopharmaceutical company developing RNA therapeutics

No salary listed

Remote in USA

Remote

Category
Business & Strategy (1)
Required Skills
Quality Assurance (QA)
Data Analysis
Requirements
  • Experience in one or more of the following: strategy consulting (healthcare exposure strongly preferred), health tech or tech-enabled services operations, clinical trial operations, or payer/member engagement
  • Demonstrated ability to use data and analytics to diagnose operational performance, identify issues, and drive measurable improvements in complex workflows
  • Proven experience building, implementing, and scaling operational processes, systems, or teams in dynamic environments
  • Experience working cross-functionally with clinical, product, and/or commercial stakeholders, with the ability to translate strategy into execution
  • Track record of ownership and accountability for outcomes, with a bias toward action and comfort operating in fast-paced, ambiguous environments
  • Strong attention to detail and willingness to operate at both a strategic and highly granular level, including direct engagement with frontline operations
  • Demonstrated curiosity, creativity, and openness to testing new approaches, including leveraging technology to improve operational performance
  • Exceptional academic background with a bachelor’s degree required; advanced degree (e.g., MBA, MPH, or related field) strongly preferred
  • Clinical background is a strong plus, though not required
Responsibilities
  • Own and improve performance across the end-to-end clinical operations funnel, including patient identification, outreach, engagement, screening, and enrollment, with accountability for measurable outcomes
  • Lead structured, data-driven analysis of operational performance to identify root causes of variation, prioritize opportunities, and design and implement high-impact interventions that improve conversion and throughput
  • Maintain close proximity to frontline operations to inform strategy, while establishing mechanisms (reporting, QA, performance management) that enable scalable oversight and continuous improvement
  • Build and scale operational infrastructure, including workflows, playbooks, training programs, reporting systems, and team structures as the organization grows
  • Partner closely with clinical, product, and commercial leaders to translate strategic priorities into operational plans and ensure effective cross-functional execution
  • Represent the company as an operational leader in sales processes and partner engagements, helping articulate the model, operational approach, and expected outcomes
  • Identify, evaluate, and implement technology and innovative approaches (e.g., AI-enabled outreach, automation, engagement strategies) to improve efficiency, scalability, and outcomes
  • Support hiring, onboarding, and management of team members and team leads, and develop capacity models aligned with client growth
Desired Qualifications
  • Advanced degree (MBA, MPH, or related field) strongly preferred
  • Clinical background is a strong plus, though not required

Roivant Sciences develops and delivers medicines, with a focus on genetic disorders and RNA therapeutics, using in-house R&D plus strategic partnerships. Its subsidiary Genevant uses proprietary delivery platforms to create RNA-based treatments, including mRNA, RNA interference, and gene editing. Revenue comes from developing drug candidates, licensing deals, partnerships, and selling approved drugs, leveraging collaborations to accelerate the pipeline. The goal is to bring effective medicines to patients faster and more efficiently by combining technology platforms with strategic alliances.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Genevant secures $2.25B settlement from Moderna, $950M upfront July 2026.
  • VTAMA generates revenue for plaque psoriasis; Dermavant expands dermatology.
  • Pulmovant in-licenses mosliciguat from Bayer for pulmonary hypertension.

What critics are saying

  • Pfizer dominates mRNA, eroding Genevant's RNAi market share immediately.
  • Brepocitinib Phase 3 fails FDA efficacy, destroying $500M pipeline value.
  • Bayer terminates Pulmovant after Phase 2 failures, cutting 30% revenue.

What makes Roivant Sciences unique

  • Roivant builds Vants as agile subsidiaries for focused drug development.
  • Genevant pioneers RNA therapeutics using mRNA, RNAi, and gene editing.
  • Datavant integrates data tools to accelerate clinical trials and evidence.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
Stock Titan
Dec 11th, 2025
Immunovant prices $550M stock offering to fund IMVT-1402 Graves' disease launch

Immunovant has priced an underwritten common stock offering of 26.2 million shares at $21.00 per share, raising approximately $550 million in gross proceeds. The company expects existing cash plus the proceeds to fund operating expenses and capital expenditures through a potential commercial launch of IMVT-1402 for Graves' disease. Roivant Sciences, Immunovant's controlling stockholder, has agreed to purchase shares in the offering. Leerink Partners is acting as sole underwriter. The offering is expected to close on or about 12 December 2025, subject to customary closing conditions. The shares are being offered pursuant to an automatic registration statement on Form S-3 previously filed with the Securities and Exchange Commission.

PsiThera
Dec 10th, 2025
PsiThera Unveiled with Newly Appointed CEO and $47.5 Million Series A to Advance Oral Medicines for Validated I&I Targets - PsiThera

Watertown, MA, December 10, 2025 — PsiThera, a biotech company harnessing biologically relevant protein states and computational intelligence to create oral drugs for diseases long-constrained by injectable-only approaches, announced today that it has closed a $47.5 million Series A financing and appointed Eric Shaff as Chief Executive Officer. The equity round was led by Samsara Biocapital…

GlobeNewswire
Sep 11th, 2025
Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List

Earning a spot means that Roivant is one of the best companies to work for in the country.

Investing.com
Feb 24th, 2025
Roivant Sciences president Eric Venker sells $1.07 million in shares

Jennifer Humes has been appointed to succeed Kumar as the new Principal Accounting Officer for Roivant Sciences Ltd. and Chief Accounting Officer for Roivant Sciences, Inc.

FinSMEs
Feb 3rd, 2025
Zest Health Raises $13M in Funding

Zest Health, a NYC-based virtual care company focused on treating patients with inflammatory skin diseases, raised $13M in Seed funding